ABSTRACT
Objective To study the influence of gamma globulin to serum B cell activating factor (BAFF) in therapy of neonatal thrombocytopenic purpura.Methods Fifteen cases with neonatal thrombocytopenic purpura(treatment group) were treated with gamma globulin.Serum BAFF levels of treatment group before and after treatment and 20 healthy neonates(control group) were tested.Results Serum BAFF level of the treatment group before treatment was(0.96±0.48) μg/L,which was statistically significant compared with that of the control group[(0.48 ±0.35) μg/L](P ＜0.05).Serum BAFF level of treatment group after treatment was (0.45 ± 0.37) μg/L,which was statistically significant compared with that of before treatment (P ＜ 0.05),but was not statistically significant compared with that of the control group.Conclusion Gamma globulin can play a role in the therapy of neonatal thrombocytopenic purpura by reducing the BAFF.